TargetMol

ABT-418

Product Code:
 
TAR-T26529
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26529-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26529-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26529-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ABT-418, a nicotinic acetylcholine receptor (nAchR) agonist, is used potentially for the treatment of attention deficit disorder.
CAS:
147402-53-7
Formula:
C9H14N2O
Molecular Weight:
166.224
Purity:
0.98
SMILES:
CN1CCC[C@H]1c1cc(C)no1

References

1. Guo T, Yang C, Guo L, Liu K. A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD. Neurosci Lett. 2012 Oct 18;528(1):11-5. doi: 10.1016/j.neulet.2012.08.068. PubMed PMID: 22985505. 2. Dallanoce C, Magrone P, Matera C, Lo Presti L, De Amici M, Riganti L, Clementi F, Gotti C, De Micheli C. Synthesis of novel chiral ?2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. Eur J Med Chem. 2010 Dec;45(12):5594-601. doi: 10.1016/j.ejmech.2010.09.009. PubMed PMID: 20932609. 3. Kenney JW, Wilkinson DS, Gould TJ. The enhancement of contextual fear conditioning by ABT-418. Behav Pharmacol. 2010 May;21(3):246-9. doi: 10.1097/FBP.0b013e32833a5b9d. PubMed PMID: 20400893; PubMed Central PMCID: PMC3042125. 4. Reichel CM, Murray JE, Barr JD, Bevins RA. Extinction with varenicline and nornicotine, but not ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of nicotine. Neuropharmacology. 2010 Jun;58(8):1237-45. doi: 10.1016/j.neuropharm.2010.03.005. PubMed PMID: 20302882; PubMed Central PMCID: PMC2881947.